Status:

COMPLETED

Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

Lead Sponsor:

Memory Pharmaceuticals

Conditions:

Alzheimer's Disease

Eligibility:

All Genders

50-90 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to determine in a 12-week treatment study if MEM 1003 is a safe and effective treatment for patients with mild to moderate Alzheimer's disease.

Detailed Description

Alzheimer's disease is the leading cause of dementia and one of the most common diseases of the aging population. It is a chronic brain disease that involves gradual memory loss, decline in the abilit...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • standardized MMSE Score of 10 to 24 points
  • diagnosis of probable Alzheimer's disease
  • magnetic resonance imaging or computed tomography examination compatible with AD
  • modified Hachinski Ischemia Score of less than or equal to 4
  • currently receiving no AD therapy or currently receiving donepezil, rivastigmine, or galantamine
  • Exclusion criteria:
  • head injury associated with cognitive impairment
  • history of vascular dementia stroke, transient cerebral ischemic episodes, major depression, major psychotic disorder, or symptomatic postural hypotension
  • treatment for Alzheimer's disease other than donepezil, rivastigmine, or galantamine; tacrine is not permitted in the last 30 days or memantine in the last 90 days
  • treatment with calcium channel blockers or any investigational medications within the prior 30 days

Exclusion

    Key Trial Info

    Start Date :

    November 1 2005

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    October 1 2007

    Estimated Enrollment :

    183 Patients enrolled

    Trial Details

    Trial ID

    NCT00257673

    Start Date

    November 1 2005

    End Date

    October 1 2007

    Last Update

    May 6 2008

    Active Locations (57)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 15 (57 locations)

    1

    Northport, Alabama, United States, 35476

    2

    Mesa, Arizona, United States, 85201

    3

    Phoenix, Arizona, United States, 85013

    4

    Sun City, Arizona, United States, 85351